{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:59Z","timestamp":1793155739773,"version":"4.5.0"},"reference-count":51,"publisher":"National Academy of Sciences","issue":"34","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"vor","delay-in-days":184,"URL":"http:\/\/www.pnas.org\/site\/misc\/userlicense.xhtml"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG"],"award-info":[{"award-number":["DFG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HA 7021\/1-1"],"award-info":[{"award-number":["HA 7021\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["Oxford NIHR Biomedical Research Centre"],"award-info":[{"award-number":["Oxford NIHR Biomedical Research Centre"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102288\/Z\/13\/Z"],"award-info":[{"award-number":["102288\/Z\/13\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2015,8,25]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Epigenetic inhibitors have shown considerable promise for the treatment of malignant and inflammatory diseases. We present here the detailed characterization of a potent and highly selective inhibitor of the bromodomains of CBP (CREB binding protein)\/p300. Functional preclinical data studying cells derived from patients with ankylosing spondylitis and psoriatic arthritis (two human Th17-driven diseases) show that selective inhibition of the CBP\/p300 bromodomain with CBP30 strongly reduces secretion of IL-17A, without having the broader and potentially deleterious effects on cytokine production and gene transcription of the pan-BET (bromo and extraterminal domain protein family) inhibitor JQ1. CBP\/p300 play a significant role in IL-17A production, and CBP\/p300 inhibition is a promising therapeutic strategy in human type-17\u2013mediated diseases such as ankylosing spondylitis and psoriatic arthritis.<\/jats:p>","DOI":"10.1073\/pnas.1501956112","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T22:30:34Z","timestamp":1439245834000},"page":"10768-10773","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":251,"title":["CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses"],"prefix":"10.1073","volume":"112","author":[{"given":"Ariane","family":"Hammitzsch","sequence":"first","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Tallant","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"},{"name":"Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"},{"name":"Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"O\u2019Mahony","sequence":"additional","affiliation":[{"name":"BioSeek Division of DiscoveRx Corporation, South San Francisco, CA 94080;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Brennan","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"},{"name":"Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan A.","family":"Hay","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando O.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"de Wit","sequence":"additional","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Vecellio","sequence":"additional","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wells","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wordsworth","sequence":"additional","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"},{"name":"Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knapp","sequence":"additional","affiliation":[{"name":"Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom;"},{"name":"Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, United Kingdom;"},{"name":"Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, 60438 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bowness","sequence":"additional","affiliation":[{"name":"Botnar Research Institute, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2015,8,10]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nsmb.2642","article-title":"Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation","volume":"20","author":"Delvecchio M","year":"2013","unstructured":"M Delvecchio, J Gaucher, C Aguilar-Gurrieri, E Ortega, D Panne, Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat Struct Mol Biol 20, 1040\u20131046 (2013).","journal-title":"Nat Struct Mol Biol"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: Epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos P","year":"2014","unstructured":"P Filippakopoulos, S Knapp, Targeting bromodomains: Epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13, 337\u2013356 (2014).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1017\/S1462399411001992","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller S","year":"2011","unstructured":"S Muller, P Filippakopoulos, S Knapp, Bromodomains as therapeutic targets. Expert Rev Mol Med 13, e29 (2011).","journal-title":"Expert Rev Mol Med"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.4049\/jimmunol.1202838","article-title":"BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses","volume":"190","author":"Belkina AC","year":"2013","unstructured":"AC Belkina, BS Nikolajczyk, GV Denis, BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 190, 3670\u20133678 (2013).","journal-title":"J Immunol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"13505","DOI":"10.1074\/jbc.R000025200","article-title":"CREB-binding protein and p300 in transcriptional regulation","volume":"276","author":"Vo N","year":"2001","unstructured":"N Vo, RH Goodman, CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 276, 13505\u201313508 (2001).","journal-title":"J Biol Chem"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/jm800657z","article-title":"Mechanism of p300 specific histone acetyltransferase inhibition by small molecules","volume":"52","author":"Arif M","year":"2009","unstructured":"M Arif, , Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. J Med Chem 52, 267\u2013277 (2009).","journal-title":"J Med Chem"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.1073\/pnas.0404875101","article-title":"A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]","volume":"101","author":"Emami KH","year":"2004","unstructured":"KH Emami, , A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 101, 12682\u201312687 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"17622","DOI":"10.1073\/pnas.0406374101","article-title":"Identification of small-molecule antagonists that inhibit an activator: Coactivator interaction","volume":"101","author":"Best JL","year":"2004","unstructured":"JL Best, , Identification of small-molecule antagonists that inhibit an activator: Coactivator interaction. Proc Natl Acad Sci USA 101, 17622\u201317627 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1021\/jm300346w","article-title":"Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites","volume":"55","author":"Vidler LR","year":"2012","unstructured":"LR Vidler, N Brown, S Knapp, S Hoelder, Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 55, 7346\u20137359 (2012).","journal-title":"J Med Chem"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos P","year":"2010","unstructured":"P Filippakopoulos, , Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme E","year":"2010","unstructured":"E Nicodeme, , Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119\u20131123 (2010).","journal-title":"Nature"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-12-3292","article-title":"PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains","volume":"73","author":"Picaud S","year":"2013","unstructured":"S Picaud, , PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res 73, 3336\u20133346 (2013).","journal-title":"Cancer Res"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson MA","year":"2011","unstructured":"MA Dawson, , Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529\u2013533 (2011).","journal-title":"Nature"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1021\/jm200640v","article-title":"3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands","volume":"54","author":"Hewings DS","year":"2011","unstructured":"DS Hewings, , 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54, 6761\u20136770 (2011).","journal-title":"J Med Chem"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"9308","DOI":"10.1021\/ja412434f","article-title":"Discovery and optimization of small-molecule ligands for the CBP\/p300 bromodomains","volume":"136","author":"Hay DA","year":"2014","unstructured":"DA Hay, , Discovery and optimization of small-molecule ligands for the CBP\/p300 bromodomains. J Am Chem Soc 136, 9308\u20139319 (2014).","journal-title":"J Am Chem Soc"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1002\/anie.201402750","article-title":"A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-\u03c0 interaction","volume":"53","author":"Rooney TP","year":"2014","unstructured":"TP Rooney, , A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-\u03c0 interaction. Angew Chem Int Ed Engl 53, 6126\u20136130 (2014).","journal-title":"Angew Chem Int Ed Engl"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1084\/jem.20130376","article-title":"BET bromodomain inhibition suppresses TH17-mediated pathology","volume":"210","author":"Mele DA","year":"2013","unstructured":"DA Mele, , BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 210, 2181\u20132190 (2013).","journal-title":"J Exp Med"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn T","year":"2009","unstructured":"T Korn, E Bettelli, M Oukka, VK Kuchroo, IL-17 and Th17 Cells. Annu Rev Immunol 27, 485\u2013517 (2009).","journal-title":"Annu Rev Immunol"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen H","year":"2009","unstructured":"H Shen, JC Goodall, JS Hill Gaston, Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60, 1647\u20131656 (2009).","journal-title":"Arthritis Rheum"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness P","year":"2011","unstructured":"P Bowness, , Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 186, 2672\u20132680 (2011).","journal-title":"J Immunol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11926-013-0356-9","article-title":"Treatment challenges in axial spondylarthritis and future directions","volume":"15","author":"Sieper J","year":"2013","unstructured":"J Sieper, Treatment challenges in axial spondylarthritis and future directions. Curr Rheumatol Rep 15, 356 (2013).","journal-title":"Curr Rheumatol Rep"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten D","year":"2013","unstructured":"D Baeten, , Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial. Lancet 382, 1705\u20131713 (2013).","journal-title":"Lancet"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.immuni.2008.12.009","article-title":"Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells","volume":"30","author":"Wei G","year":"2009","unstructured":"G Wei, , Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30, 155\u2013167 (2009).","journal-title":"Immunity"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.immuni.2011.10.019","article-title":"Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2","volume":"36","author":"Wang X","year":"2012","unstructured":"X Wang, , Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2. Immunity 36, 23\u201331 (2012).","journal-title":"Immunity"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-8935-7-14","article-title":"Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching","volume":"7","author":"Philpott M","year":"2014","unstructured":"M Philpott, , Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Epigenetics Chromatin 7, 14 (2014).","journal-title":"Epigenetics Chromatin"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nchembio.1471","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Ciceri P","year":"2014","unstructured":"P Ciceri, , Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10, 305\u2013312 (2014).","journal-title":"Nat Chem Biol"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vascn.2009.10.001","article-title":"Chemical target and pathway toxicity mechanisms defined in primary human cell systems","volume":"61","author":"Berg EL","year":"2010","unstructured":"EL Berg, , Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods 61, 3\u201315 (2010).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","article-title":"c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells","volume":"123","author":"Roderick JE","year":"2014","unstructured":"JE Roderick, , c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040\u20131050 (2014).","journal-title":"Blood"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","article-title":"Small-molecule inhibition of BRDT for male contraception","volume":"150","author":"Matzuk MM","year":"2012","unstructured":"MM Matzuk, , Small-molecule inhibition of BRDT for male contraception. Cell 150, 673\u2013684 (2012).","journal-title":"Cell"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","article-title":"The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States","volume":"345","author":"Reveille JD","year":"2013","unstructured":"JD Reveille, MH Weisman, The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci 345, 431\u2013436 (2013).","journal-title":"Am J Med Sci"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean LE","year":"2014","unstructured":"LE Dean, , Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 53, 650\u2013657 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci","volume":"45","author":"Cortes A","year":"2013","unstructured":"A Cortes, , Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet; International Genetics of Ankylosing Spondylitis Consortium (IGAS); Australo-Anglo-American Spondyloarthritis Consortium (TASC); Groupe Fran\u00e7aise d\u2019Etude G\u00e9n\u00e9tique des Spondylarthrites (GFEGS); Nord-Tr\u00f8ndelag Health Study (HUNT); Spondyloarthritis Research Consortium of Canada (SPARCC); Wellcome Trust Case Control Consortium 2 (WTCCC2) 45, 730\u2013738 (2013).","journal-title":"Nat Genet"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans DM","year":"2011","unstructured":"DM Evans, , Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet; Spondyloarthritis Research Consortium of Canada (SPARCC); Australo-Anglo-American Spondyloarthritis Consortium (TASC); Wellcome Trust Case Control Consortium 2 (WTCCC2) 43, 761\u2013767 (2011).","journal-title":"Nat Genet"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes IB","year":"2013","unstructured":"IB McInnes, , Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet; PSUMMIT 1 Study Group 382, 780\u2013789 (2013).","journal-title":"Lancet"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester GR","year":"2013","unstructured":"GR Burmester, , Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis; EARTH Study Group 72, 1445\u20131452 (2013).","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus C","year":"2008","unstructured":"C Jandus, , Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58, 2307\u20132317 (2008).","journal-title":"Arthritis Rheum"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2012.09.016","article-title":"A validated regulatory network for Th17 cell specification","volume":"151","author":"Ciofani M","year":"2012","unstructured":"M Ciofani, , A validated regulatory network for Th17 cell specification. Cell 151, 289\u2013303 (2012).","journal-title":"Cell"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen SL","year":"2014","unstructured":"SL Gaffen, R Jain, AV Garg, DJ Cua, The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol 14, 585\u2013600 (2014).","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"19286","DOI":"10.1073\/pnas.0905469106","article-title":"Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes","volume":"106","author":"Byun JS","year":"2009","unstructured":"JS Byun, , Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes. Proc Natl Acad Sci USA 106, 19286\u201319291 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato F","year":"2007","unstructured":"F Annunziato, , Phenotypic and functional features of human Th17 cells. J Exp Med 204, 1849\u20131861 (2007).","journal-title":"J Exp Med"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.4049\/jimmunol.180.11.7423","article-title":"Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes","volume":"180","author":"P\u00e8ne J","year":"2008","unstructured":"J P\u00e8ne, , Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180, 7423\u20137430 (2008).","journal-title":"J Immunol"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135245859900500206","article-title":"Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis","volume":"5","author":"Matusevicius D","year":"1999","unstructured":"D Matusevicius, , Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5, 101\u2013104 (1999).","journal-title":"Mult Scler"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-61779-337-0_7","article-title":"Kinase inhibitor selectivity profiling using differential scanning fluorimetry","volume":"795","author":"Fedorov O","year":"2012","unstructured":"O Fedorov, FH Niesen, S Knapp, Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol Biol 795, 109\u2013118 (2012).","journal-title":"Methods Mol Biol"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch W","year":"2010","unstructured":"W Kabsch, Xds. Acta Crystallogr D Biol Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1107\/S090744491003982X","article-title":"An introduction to data reduction: Space-group determination, scaling and intensity statistics","volume":"67","author":"Evans PR","year":"2011","unstructured":"PR Evans, An introduction to data reduction: Space-group determination, scaling and intensity statistics. Acta Crystallogr D Biol Crystallogr 67, 282\u2013292 (2011).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/nprot.2008.91","article-title":"Automated macromolecular model building for X-ray crystallography using ARP\/wARP version 7","volume":"3","author":"Langer G","year":"2008","unstructured":"G Langer, SX Cohen, VS Lamzin, A Perrakis, Automated macromolecular model building for X-ray crystallography using ARP\/wARP version 7. Nat Protoc 3, 1171\u20131179 (2008).","journal-title":"Nat Protoc"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-building tools for molecular graphics","volume":"60","author":"Emsley P","year":"2004","unstructured":"P Emsley, K Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov GN","year":"1997","unstructured":"GN Murshudov, AA Vagin, EJ Dodson, Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240\u2013255 (1997).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: A tool for high-throughput crystallography of protein-ligand complexes","volume":"60","author":"Sch\u00fcttelkopf AW","year":"2004","unstructured":"AW Sch\u00fcttelkopf, DM van Aalten, PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60, 1355\u20131363 (2004).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: All-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen VB","year":"2010","unstructured":"VB Chen, , MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","unstructured":"FO Martinez Analysis of gene expression and gene silencing in human macrophages. Curr Protoc Immunol Suppl 96 Unit 14.28 pp 14.28.1\u201314.28.23. (2012).","DOI":"10.1002\/0471142735.im1428s96"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1501956112","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1501956112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T08:56:58Z","timestamp":1654592218000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1501956112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,10]]},"references-count":51,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2015,8,25]]}},"alternative-id":["10.1073\/pnas.1501956112"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1501956112","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725713170.793551648","asserted-by":"object"}]},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,10]]},"assertion":[{"value":"2015-08-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}